OMass Therapeutics
An Oxford biotech developing small-molecule medicines using structural mass spectrometry to study complex protein targets in their native environment.
Europe's most interesting startup stories. Every week.
No spam. Unsubscribe anytime.
Podcast Episode
🎙️ Deep Dive
Bending Spoons, OMass, Salience Labs — $330M from Berkshire, $310M for biotech and $125M for photonic chips — Daily News October 15, 2026
Listen to the episodeAbout OMass Therapeutics
Founded in 2016 as OMass Technologies from Professor Dame Carol Robinson’s lab at the University of Oxford and relaunched as OMass Therapeutics in 2018, the company turned that research into its OdyssION platform. Its internal pipeline targets endocrinology and immunology: lead programme OMS1620 is an MC2 receptor antagonist in development for congenital adrenal hyperplasia and ACTH-dependent Cushing’s syndrome, while an SLC15A4 inhibitor is aimed at lupus. On October 15, 2026, it announced an oversubscribed $310 million Series C co-led by Bain Capital Life Sciences, Forbion and Novo Holdings.
The Story
A spinout from Dame Carol Robinson’s lab at the University of Oxford, established in 2016 as OMass Technologies and renamed OMass Therapeutics in 2018, the year of its £14 million Series A led by Syncona.
How OMass Therapeutics works
Business Model
Proprietary pipeline development with potential partnerships and licences with pharmaceutical companies.
Revenue Model
No commercial revenue reported; potential licensing deals and, after any approvals, drug sales.
Products & Services
Key Products
- OdyssION platform
- OMS1620 (MC2 receptor antagonist)
- SLC15A4 inhibitor
Core Use Cases
- Small-molecule drug discovery
- Structural analysis of proteins and complexes
- Clinical development in endocrinology and immunology
Market & Clients
Key Customers
Pharmaceutical partners; patients and healthcare providers only after any approvals.
Geographic Presence
How OMass Therapeutics competes
Competitive Advantages
- Proprietary OdyssION platform
- Native mass spectrometry applied to difficult targets
- Internally discovered pipeline
How OMass Therapeutics grows
Growth Strategy
Advance OMS1620 through Phase 2, generate initial clinical data on SLC15A4 and broaden the pipeline.
Distribution Model
Proprietary development with potential partnerships and licences; future commercialisation depends on approvals.
Moat (Defensibility)
Scientific know-how transferred from the University of Oxford, proprietary experimental data and integrated discovery-to-clinic capabilities.
Regulatory Context
Clinical-trial authorisations, safety and efficacy assessment and drug approvals in target markets.
Key Risks
- Clinical failure or safety issues
- Clinical-trial timelines and costs
- Competition from approved or developing therapies
Strategic Insights
- A $310 million round makes it possible to reach Phase 2 data without immediately relying on a pharmaceutical partner.
- The platform gains value only if it produces clinical candidates that pass efficacy tests.
Funding & Investors
Funding Rounds
- 2018 - Series A: £14M
Lead: Syncona - 2026 - Series C: $310M (£230M)
Lead: Bain Capital Life Sciences, Forbion, Novo Holdings
Key Investors
Founding Team
Founders
Key Executives
- Ros Deegan - Chief Executive Officer
Key Metrics
Lessons from OMass Therapeutics
- In spinout biotech, the step from technology to clinical pipeline decides how much capital can be attracted.
Similar Startups
Ternary Therapeutics
London biotech founded in 2024 designing molecular glues with AI. In March 2026 it announced a €4.1 million seed.
Read AnalysisOxford Medical Simulation
UK clinical-simulation company using VR and AI, founded in 2017. On 16 March 2026 it announced £5 million of growth financing from Salica.
Read AnalysisBioniq
London company founded in 2019 offering supplement formulas personalised from a customer assessment. In 2026 Herbalife acquired its core assets.
Read AnalysisSources
- OMass Therapeutics Announces $310 Million Series C Financing — OMass Therapeutics / GlobeNewswire
- Oxford University spinout OMass Therapeutics raises $310m — The Times
- Axios Pro Rata: Founders vs. fiduciaries — Axios
- OMass Therapeutics: New technology for drug discovery and development — University of Oxford
- OMass amasses $17.9m series A — Global University Venturing